Cellectis (CLLS) News Today $2.24 -0.03 (-1.32%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 3, 2024 | globenewswire.comCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving SafetySeptember 3, 2024 | americanbankingnews.comCellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.comSeptember 2, 2024 | uk.finance.yahoo.comCellectis S.A. (0WA2.IL)September 2, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.comStockNews.com started coverage on shares of Cellectis in a report on Monday. They issued a "sell" rating for the company.September 1, 2024 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Sees Significant Drop in Short InterestCellectis S.A. (NASDAQ:CLLS - Get Free Report) was the target of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 395,400 shares, a decline of 10.3% from the July 31st total of 440,700 shares. Based on an average daily volume of 53,700 shares, the days-to-cover ratio is currently 7.4 days.August 30, 2024 | seekingalpha.comCellectis: Cheap With Promising But Speculative Cancer TherapiesAugust 28, 2024 | uk.finance.yahoo.comCellectis SA (ZVAA.DU)August 28, 2024 | americanbankingnews.comCellectis (NASDAQ:CLLS) vs. Fresh Tracks Therapeutics (NASDAQ:FRTX) Head to Head ContrastAugust 26, 2024 | globenewswire.comCellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid TumorsAugust 26, 2024 | marketbeat.comBaillie Gifford & Co. Sells 119,618 Shares of Cellectis S.A. (NASDAQ:CLLS)Baillie Gifford & Co. reduced its position in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 14.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 707,630 shares of the biotechnology company's stock after selling 119,61August 25, 2024 | marketbeat.comStockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)StockNews.com initiated coverage on shares of Cellectis in a research note on Sunday. They issued a "sell" rating on the stock.August 10, 2024 | markets.businessinsider.comCellectis SA: Strong Buy Rating on Robust Pipeline and Financial StabilityAugust 8, 2024 | msn.comCellectis Non-GAAP EPS of -$0.22 beats by $0.09, revenue of $9.5M misses by $0.2MAugust 7, 2024 | globenewswire.comCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical OfficerAugust 7, 2024 | markets.businessinsider.comCLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024August 6, 2024 | msn.comCellectis GAAP EPS of -$0.28 beats by $0.02, revenue of $9.5M beats by $5.77MAugust 6, 2024 | globenewswire.comCellectis Provides Financial Results for the Second Quarter 2024August 3, 2024 | stockhouse.comFDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 2, 2024 | finanznachrichten.deCellectis Inc.: FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 2, 2024 | marketwatch.comCellectis Gets Orphan Designation for Drug Used in Cancer TreatmentAugust 1, 2024 | finance.yahoo.comFDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL TreatmentAugust 1, 2024 | globenewswire.comFDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 1, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.comStockNews.com began coverage on shares of Cellectis in a research note on Thursday. They issued a "sell" rating on the stock.July 25, 2024 | globenewswire.comFDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) TreatmentJune 30, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.comStockNews.com assumed coverage on Cellectis in a research note on Sunday. They set a "sell" rating on the stock.June 28, 2024 | globenewswire.comCellectis Reports Results from Shareholders Meeting Held on June 28, 2024June 20, 2024 | globenewswire.comCellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingJune 16, 2024 | marketbeat.comShort Interest in Cellectis S.A. (NASDAQ:CLLS) Decreases By 16.8%Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large decline in short interest in May. As of May 31st, there was short interest totalling 424,200 shares, a decline of 16.8% from the May 15th total of 509,900 shares. Based on an average daily volume of 46,700 shares, the short-interest ratio is presently 9.1 days.June 12, 2024 | globenewswire.comCellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsJune 4, 2024 | globenewswire.comCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaMay 31, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Rating Reiterated by JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $6.00 price target on shares of Cellectis in a report on Friday.May 29, 2024 | finance.yahoo.comCellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024May 29, 2024 | globenewswire.comCellectis' Annual Shareholders General Meeting to be Held on June 28, 2024May 29, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Share Price Passes Below 50-Day Moving Average of $2.75Cellectis (NASDAQ:CLLS) Share Price Passes Below 50 Day Moving Average of $2.75May 28, 2024 | investorplace.comCLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024May 27, 2024 | globenewswire.comCellectis to Report First Quarter 2024 Financial Results on May 28, 2024May 6, 2024 | globenewswire.comCellectis Announces Completion of the Additional Equity Investment by AstraZenecaMay 2, 2024 | globenewswire.comCellectis Appoints Arthur Stril as Interim Chief Financial OfficerMay 1, 2024 | benzinga.comCellectis Stock (NASDAQ:CLLS), Earnings Estimates, EPS, and RevenueApril 29, 2024 | globenewswire.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2023April 24, 2024 | seekingalpha.comCLLS Cellectis S.A.April 22, 2024 | globenewswire.comCellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsApril 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Decline in Thursday TradingApril 10, 2024 | finance.yahoo.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsApril 10, 2024 | globenewswire.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsApril 8, 2024 | globenewswire.comCellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingApril 1, 2024 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Sees Significant Decrease in Short InterestCellectis S.A. (NASDAQ:CLLS - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 679,300 shares, a decline of 6.6% from the February 29th total of 727,500 shares. Based on an average daily trading volume, of 50,500 shares, the days-to-cover ratio is presently 13.5 days.March 27, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday TradingMarch 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday TradingFebruary 27, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Share Price Crosses Below 50 Day Moving Average of $2.99Cellectis (NASDAQ:CLLS) Shares Pass Below 50 Day Moving Average of $2.99 Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address The solution to fast food’s wage hike crisis (Ad)Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032. Learn more about this much-needed advancement and investment opportunity here. CLLS Media Mentions By Week CLLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLLS News Sentiment▼0.370.55▲Average Medical News Sentiment CLLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLLS Articles This Week▼51▲CLLS Articles Average Week Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VALN News FULC News CMPS News QTTB News OCS News ERAS News TERN News AVXL News ALEC News ALT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLLS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
